[18F]Fluciclatide PET Imaging of Pazopanib Response

Inclusion Criteria:

• Histologically confirmed renal cell carcinoma, stage IV patient.
• The tumor mass ≥1.5cm in diameter that is planned to receive Pazopanib as systemic antiangiogenic therapy.
• Pretreatment CT with or without contrast within 4 weeks prior to the first 18F-Fluciclatide PET scan.
• Evidence of unidimensionally measurable lesion(s) by RECIST criteria version 1.1.
• No prior systemic anti-angiogenic therapy for metastatic disease; prior antiangiogenic therapy used as an adjuvant therapy is allowed if it is completed 6 or more months before study enrollment.
• Male or female aged over 20 years
• Be ambulatory and have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Have a life expectancy of at least 3 months.
• Adequate medical condition in the judgment of the investigator
• Be willing and able to comply with the protocol for the duration of the study.
• Be willing and able to implement effective contraceptive practice
• Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

Exclusion Criteria:

• Received another IMP within 30 days before the first administration of 18F-Fluciclatide injection.
• Inability to perform 18F-Fluciclatide PET imaging studies due to physical inability or claustrophobia.
• Intra-hepatic tumor only (without extra-hepatic tumor)
• Chemotherapy within 2weeks, or received radiotherapy to the region of the target lesion, surgery of target lesion within 2 weeks prior to the first 18F-Fluciclatide PET scan
• Pregnant, nursing women or patients with reproductive potential without contraception.
• Current treatment on another therapeutic clinical trial(except Pazopanib study)
• Any patients with known allergy to the GE health care product or any or its excipients should be excluded from the study
• Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.